Pyridylthiophene compounds

Details Pyridylthiophene compounds Pyridylthiophene compounds

2001-07-30

2004-02-24

Fan, Jane (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S337000, C546S256000, C546S280100, C546S281100, C546S279700

Reexamination Certificate

active

06696470

ABSTRACT:

TECHNICAL FIELD
This invention relates to novel pyridylfuran and pyridylthiophene compounds, their pharmaceutically effective salts, processes for the preparation thereof, the use thereof in treating cytokine mediated diseases and/or cell adhesion molecule mediated diseases, and pharmaceutical compositions for use in such therapy.
BACKGROUND ART
Cytokines possess a multitude of regulatory and inflammatory effects. Interleukin-1 (IL-1) and Tumor Necrosis Factor (TNF) are biological substances produced by a variety of cells, such as monocytes or macrophages. IL-1 has been demonstrated to mediate a variety of biological activities thought to be important in immunoregulation and other physiological conditions such as inflammation.
There are many disease states in which excessive or unregulated IL-1 production is implicated in exacerbating and/or causing the disease. These include rheumatoid arthritis (RA), osteoarthritis (OA), endotoxemia and/or toxic shock syndrome, other acute and chronic inflammatory disease states such as the inflammatory reaction induced by endotoxin or inflammatory bowel disease (IBD), tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, Reiter's syndrome, gout, traumatic arthritis, rubella arthritis and acute synovitis. Recent evidence also links IL-1 activity to diabetes.
Excessive or unregulated TNF production has been implicated in mediating or exacerbating a number of diseases including RA, rheumatoid spondylitis, OA, gouty arthritis and other arthritic conditions, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome (ARDS), cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption diseases, reperfusion injury, graft vs. host reaction, allograft rejections, fever and myalgias due to infection such as influenza, cachexia secondary to infection or malignancy, cachexia, cancer, secondary to acquired immune deficiency syndrome (AIDS), ARC (AIDS related complex), keloid formation, diabetes, obesity, scar tissue formation. Crohn's disease, ulcerative colitis or pyresis. The concept of anti-TNF therapy has been validated by the demonstration that soluble TNF receptor and neutralizing monoclonal antibodies (MAbs) against TNF showed therapeutic efficacy in a variety of preclinical and clinical studies (e.g., Elliott, M. J. et al.,
The Lancet,
1994, 344, 1125. Dullemen, H. M. V. et al.,
Gastroenterology,
1995. 109, 129.)
Interleukin-8 (IL-8) is a chemotactic factor first identified and characterized in 1987. IL-8 is produced by several cell types including neutrophils, mononuclear cells, fibroblasts, endothelial cells, epithelial cells and keratinocytes. Elevated IL-8 levels have been reported in joint fluids in RA, gouty arthritis, psoriatic scale and ARDS. Its production from endothelial cells is induced by IL-1, TNF or lipopolysachharide (LPS). IL-8 has been shown to have chemoattractant properties for neutrophils, T-lymphocytes and basophils. In addition, it promotes angiogenesis as well as neutrophil activation, including lysozomal enzyme release and respiratory burst. IL-8 has also been shown to increase the surface expression of Mac-1 (CD11b/CD18) on neutrophils, which may contribute to increased adhesion of the neutrophils to vascular endothelial cells. Many diseases are characterized by massive neutrophil infiltration. Conditions associated with an increased IL-8 production would benefit by compounds which suppress of IL-8 production.
Cellular movement and adhesion are a fundamental biological response to external stimuli. During an inflammatory response, leukocytes must leave the plasma compartment and migrate to the point of antigenic insult. The mechanism of this migratory event is a complex interplay between soluble mediators and membrane-bound cellular adhesion molecules. Soluble cellular chemotactic factors, which are produced in the damaged tissue by a variety of resident cells, set up a chemical concentration gradient out to the plasma compartment. Interaction of these factors with their receptors on leukocytes leads to a directional migration of the leukocytes toward increasing concentrations of the chemotactic factor. Simultaneously, various adhesion molecules are upregulated on the leukocyte which mediate the initial rolling on the endothelial tissue, binding to a specific ligand on the activated endothelial tissue, and finally migration between endothelial cells into the tissue. The steps in this cascade of events are mediated by the interaction of specific cell surface proteins, termed “cell adhesion molecules (CAM)”. E-selectin (ELAM-1, endothelial leukocyte adhesion molecule-1), ICAM-1 (intercellular adhesion molecule-1), and VCAM-1 (vascular cell adhesion molecule-1) are three major adhesion molecules the expression of which on endothelial cells is upregulated upon treatment with inflammatory stimuli. ICAM-1 is expressed at low levels on resting endothelium and is markedly induced in response to cytokines such as IL-1, TNF and interferon-&ggr; (IFN-&ggr;). VCAM-1 is not expressed in resting endothelium but is induced by IL-1, TNF and IL-4. Induction of both ICAM-1 and VCAM-1 occurs 4 to 6 hours after cytokine treatment and cell surface expression remains elevated for up to 72 hours after treatment with cytokines. On the other hand, induction of transcription of the E-selectin gene by cytokines such as IL-1 and TNF results in an increase in the expression on the surface of endothelial cells peaking approximately 4-6 hours after challenge, and returns toward a basal level of expression by 24 hours.
The concept of anti-CAM therapy has been validated by the demonstration that MAbs against ICAM-1 and antisense oligonucleotide against ICAM-1 showed therapeutic efficacy in a variety of preclinical and clinical studies (A. F. Kavanaugh et al.,
Arthritis Rheum,
1994, 37, 992; C. E. Haug et al.,
Transplantation,
1993, 55, 766; and J. E. Jr. Sligh et al.,
Proc. Natl. Acad. Sci.,
1993, 90, 8529). Further support comes from the reports of the in vivo activity of sLeX and related carbohydrates, which are antagonists of E-selectin mediated adhesion ( M. S. Mulligan et al.,
Nature,
1993, 364, 149-151). Thus, the potential therapeutic targets for CAM inhibitors range from, but are not limited to, RA, IBD and psoriasis to ischemia/reperfusion injury, autoimmune diabetes, organ transplantation, ARDS, tumor metastases and AIDS, as is evident from the many ongoing development activities. The regulation of the functions of CAM is of benefit in controlling, reducing and alleviating many of these disease states. There remains a need for compounds which are capable of inhibiting cytokine production and/or CAM expression. The pyridylfuran and pyridylthiophene compounds of the present invention are shown herein in an in vitro assay to inhibit cytokine production and/or CAM expression.
Japanese Kokai (laid-open) Publication Number H02-289548 discloses aryl substituted pyridine compounds as anti-ischemia agents. Japanese Kokai (laid-open) Publication Number H03-232884 discloses a variety of thiophene compounds as a herbicide.
BRIEF DISCLOSURE OF THE INVENTION
The present invention provides a compound of the formula:
and its pharmaceutically effective salts, wherein
R
1
and R
2
are independently selected from the following:
(a) hydrogen, halo, R
5
—, R
6
—, C
2-6
alkenyl, C
2-6
alkynyl, hydroxy-R
5
—, R
5
—O—, R
5
—S—, hydroxy-R
6
—, R
5
—O—R
5
—, mercapto-R
5
—, R
5
—S—R
5
—, —NH
2
, R
5
—NH—, R
6
—NH—, (R
5
)
2
—N— or heterocyclic group optionally substituted by one or two substituents selected from C
1-4
alkyl, phenyl and pyridyl;
(b) Ar—, Ar—R
5
—, Ar—C
2-6
alkenyl, Ar—C
2-6
alkynyl, Ar—O—, Ar—O—Ar—, Ar—O—Ar—O—, Ar—O—R
5
—, Ar—R
5
—O—, Ar—S—, Ar—R
5
—S—, Ar—NH—, (Ar)
2
—R
5
—, Ar—R
5
—NH—, Ar—R
5
—N(R
5
)— or (Ar)
2
—N—;
(c) R
5
—C(O)—, —NO
2
, cyano, NH
2
—C(O)—, R
5
—NH—C(O)—, (R
5
)
2
—N—C(O)—, Ar—C(O)—, (Ar—R
5
)
2
—N—C(O)—, Ar—R
5
—C(O)—, Ar—NH—C(O)—, Ar—R
5
—NH—C(O)—, R
5
—S(O)
2
— or

Affiliated with

Also associated with

Rating

Pyridylthiophene compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyridylthiophene compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridylthiophene compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3284596